CIT-013 150mg subcutaneous Phase 1 trial healthy adults
Summary
National Library of Medicine registered CIT-013 Phase 1 clinical trial (NCT07499908) on ClinicalTrials.gov. The single-center study evaluates 150mg subcutaneous formulation in healthy adults. Trial sponsors and investigators must register and update results per FDA requirements.
What changed
ClinicalTrials.gov added a new Phase 1 trial registration for CIT-013 (150mg subcutaneous formulation) in healthy adults under NCT07499908. The record includes standard trial metadata including phase (Phase 1), intervention type, enrollment target, and study design. Single-arm or comparator details are not specified in this registration entry.
Pharmaceutical companies and clinical investigators conducting interventional drug trials in the US must register on ClinicalTrials.gov within 21 days of enrollment of the first participant (42 CFR Part 11). Sponsors should verify this trial registration is current and results are submitted within 12 months of primary completion date. Non-registration may result in civil monetary penalties of up to $10,000 per day.
What to do next
- Verify trial NCT07499908 registration status and update if enrollment status changes
- Submit results to ClinicalTrials.gov within 12 months of primary completion date
- Ensure all responsible parties are correctly listed in the trial registry record
Penalties
Civil monetary penalties of up to $10,000 per day for failure to register clinical trial or submit results as required under 42 CFR Part 11
Source document (simplified)
Show glossary
CFR references
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.